Data that empower: The success and promise of CF patient registries

Pediatric Pulmonology

Volumn 52, Issue , 2017, Pages S44-S51

  Fink, Aliza K ^a   Loeffler, Deena R ^a   Marshall, Bruce C ^a   Goss, Christopher H ^b   Morgan, Wayne J ^c  

^a CYSTIC FIBROSIS FOUNDATION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

cystic fibrosis; epidemiology; patient registry; quality improvement; registries

Indexed keywords

ANTIBIOTIC AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DORNASE ALFA; TOBRAMYCIN;

COMPARATIVE EFFECTIVENESS; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE REGISTRY; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE; HUMAN; INCIDENCE; LUNG FUNCTION; LUNG INFECTION; LUNG TRANSPLANTATION; MORTALITY; MULTIPLE CYCLE TREATMENT; NUTRITION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL; MEDICAL RESEARCH; REGISTER;

BIOMEDICAL RESEARCH; CYSTIC FIBROSIS; HUMANS; REGISTRIES;

EID: 85029458991     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23790     Document Type: Review

References (88)

1. Morgan WJ. Plenary Session 3: You Can Observe a Lot By Just Watching: Lessons from the CF Foundation Patient Registry. North American Cystic Fibrosis Conference 2016; https://www.youtube.com/watch?v=l53Tu1_WHSw
2. Lohr S. Big Data's Impact in the World. New York Times. Feb. 11, 2012; Sunday Review: SR1.
3. Dreyer N, Garner S. Registries for robust evidence. JAMA. 2009; 302:2.
4. Gliklich R, Dreyer N, Leavy M. Registries for Evaluating Patient Outcomes: A User's Guide. 3rd ed. Rockville, MD: AHRQ Publication No. 13(14)-EHC111; 2014.
5. Knapp EA, Fink AK, Goss CH, et al. The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry. Ann Am Thorac Soc. 2016; 13:1173–1179.
6. Cystic Fibrosis Canada. The Canadian CF Registry Annual Report. 2014.
7. The Brazilian Cystic Fibrosis Study Group (GBEFC). The Brazilian Cystic Fibrosis Patient Registry Annual Report. 2014.
8. BethesdaMDCystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2015 Annual Data Report. 2016.
9. Zolin A, McKone EF, van Rens J, et al. ECFSPR Annual Report 2014. 2016.
10. UK CF Trust. UK Cystic Fibrosis Registry 2015 Annual Data Report. August 2016.
11. Nederlandse Cystic Fibrosis Stichting. Dutch Cystic Fibrosis Registry 2015 Report. 2016.
12. Cystic Fibrosis Registry of Ireland. 2015 Annual Report. Dublin, Ireland 2017.
13. Mukoviszidose Institut. Qualitätssicherung Mukoviszidose (Annual Report). 2013.
14. French CFVaincre la Mucoviscidose and Ined. Registry − Annual Data Report 2013. Paris, November 2015.
15. Belgisch Mucoviscidose Register − Registre Belge de la Mucoviscidose. The Belgian Cystic Fibrosis Registry Summary Report 2011. Brussels, 2014.
16. Bell SC, Bye PTP, Cooper PJ, et al. Cystic fibrosis in Australia, 2009: results from a data registry. Med J Aust. 2011; 195:396–400.
17. Cystic Fibrosis Association of New Zealand. 2015 Annual Report. Riccarton, Christchurch, New Zealand 2016.
18. Cystic Fibrosis Australia. Cystic Fibrosis in Australia 2014: 17th Annual Report. North Ryde, Australia 2016.
19. Morgan WJ, Colin AA, Stryker S, et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol. 1999; 28:231–241.
20. Burgel PR, Bellis G, Olesen HV, et al. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J. 2015; 46:133–141.
21. Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R. Gender differences in outcomes of patients with cystic fibrosis. J Womens Health (Larchmt). 2014; 23:1012–1020.
22. Buu MC, Sanders LM, Mayo JA, Milla CE, Wise PH. Assessing differences in mortality rates and risk factors between Hispanic and non-Hispanic patients with cystic fibrosis in California. Chest. 2016; 149:380–389.
23. O'Connor GT, Quinton HB, Kneeland T, et al. Median household income and mortality rate in cystic fibrosis. Pediatrics. 2003; 111:e333–e339.
24. Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med. 2001; 163:1331–1337.
25. US CF FoundationThe Clinical and Functional TRanslation of CFTR (CFTR2). Copyright 2011, Johns Hopkins University, The Hospital for Sick Children. Available at http://cftr2.org
26. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet. 2003; 361:1671–1676.
27. McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. CHEST. 2006; 130:1441–1447.
28. Collaco JM, Blackman SM, McGready J, Naughton KM, Cutting GR. Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. J Pediatr 2010; 157:802–807. e801-803.
29. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2015; 16:45–56.
30. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001; 153:345–352.
31. Yen EH, Quinton H, Borowitz D. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr. 2013; 162:530–535 e531.
32. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol. 1988; 41:583–591.
33. Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007; 151:134–139. 139.e131.
34. McColley SA, Schechter MS, Morgan WJ, Pasta DJ, Craib ML, Konstan MW. Risk factors for mortality before age 18 years in cystic fibrosis. Pediatr Pulmonol. 2017; 52:909–915.
35. Cogen J, Emerson J, Sanders DB, et al. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol. 2015; 50:763–770.
36. Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. 2012; 40:61–66.
37. Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW. Forced expiratory volume in 1 second variability helps identify patients with cystic fibrosis at risk of greater loss of lung function. J Pediatr. 2016; 169:116–121.e112.
38. 1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2011; 46:393–400.
39. VanDevanter DR, Morris NJ, Konstan MW. IV-treated pulmonary exacerbations in the prior year: an important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2016; 15:372–379.
40. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995–2005. CHEST. 2009; 136:1554–1560.
41. Salsgiver EL, Fink AK, Knapp EA, et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. CHEST. 2015; 149:390–400.
42. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34:91–100.
43. Mayer-Hamblett N, Kloster M, Rosenfeld M, et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long-term outcomes in cystic fibrosis. Clin Infect Dis. 2015; 61:707–715.
44. Rosenfeld M, Emerson J, McNamara S, et al. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis EPIC observational cohort. J Cyst Fibros. 2012; 11:446–453.
45. Emond MJ, Louie T, Emerson J, et al. Exome sequencing of phenotypic extremes identifies CAV2 and TMC6 as interacting modifiers of chronic Pseudomonas aeruginosa infection in cystic fibrosis. PLoS Genet. 2015; 11:e1005273.
46. Emond MJ, Louie T, Emerson J, et al. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet. 2012; 44:886–889.
47. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010; 303:2386–2392.
48. Binder AM, Adjemian J, Olivier KN, Prevots DR. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med. 2013; 188:807–812.
49. Quon BS, Psoter K, Mayer-Hamblett N, Aitken ML, Li CI, Goss CH. Disparities in access to lung transplantation for patients with cystic fibrosis by socioeconomic status. Am J Respir Crit Care Med. 2012; 186:1008–1013.
50. Ramos KJ, Quon BS, Psoter KJ, et al. Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United States. J Cyst Fibros. 2016; 15:196–203.
51. Vock DM, Durheim MT, Tsuang WM, et al. Survival benefit of lung transplantation in the modern era of lung allocation. Ann Am Thorac Soc. 2017; 14:172–181.
52. Liou TG, Adler FR, Cahill BC, et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA. 2001; 286:2683–2689.
53. Thabut G, Christie JD, Mal H, et al. Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation. Am J Respir Crit Care Med. 2013; 187:1335–1340.
54. Maisonneuve P, Fitzsimmons SC, Neglia JP, Campbell PW III, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-Year study. J Natl Cancer Inst. 2003; 95:381–387.
55. Warwick WJ, Pogue RE, Gerber HU, Nesbitt CJ. Survival patterns in cystic fibrosis. J Chronic Dis. 1975; 28:609–622.
56. Sykes J, Stanojevic S, Goss CH, et al. A standardized approach to estimating survival statistics for population-based cystic fibrosis registry cohorts. J Clin Epidemiol. 2016; 70:206–213.
57. MacKenzie T, Gifford AH, Sabadosa KA, et al. Longevity of patients with cystic fibrosis in 2000–2010 and beyond: survival analysis of the Cystic Fibrosis Foundation Patient Registry. Ann Intern Med. 2014; 161:233–241.
58. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med. 2002; 166:1550–1555.
59. 1 <30% of predicted in the United States. CHEST. 2017; 151:1320–1328.
60. Carson SS, Goss CH, Patel SR, et al. An official American Thoracic Society research statement: comparative effectiveness research in pulmonary, critical care, and sleep medicine. Am J Respir Crit Care Med. 2013; 188:1253–1261.
61. Rothman KJ, Wentworth CE, 3rd. Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation. Epidemiology. 2003; 14:55–59.
62. Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA. 2016; 316:1818–1819.
63. Sawicki GS, Signorovitch JE, Zhang J, et al. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol. 2012; 47:44–52.
64. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999; 340:23–30.
65. Johnson CA, Butler SM, Konstan MW, Breen TJ, Morgan WJ. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. J Pediatr. 1999; 134:734–739.
66. Sawicki GS, McKone EF, Pasta DJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015; 192:836–842.
67. Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017; 5:107–118.
68. Bessonova L, Higgins M, Volkova N, et al. Analysis of real-world outcomes in patients with CF treated with ivacaftor from the 2014 US and UK CF registries. Pediatr Pulmonol. 2016; 51:S194–S485.
69. Sawicki GS, Dasenbrook E, Fink AK, Schechter MS. Rate of uptake of ivacaftor use after U.S. food and drug administration approval among patients enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry. Ann Am Thorac Soc. 2015; 12:1146–1152.
70. Stephenson AL, Sykes J, Stanojevic S, et al. Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study. Ann Intern Med. 2017; 166:537–546.
71. Goss CH, MacNeill SJ, Quinton HB, et al. Children and young adults with CF in the USA have better lung function compared with the UK. Thorax. 2015; 70:229–236.
72. Ostrenga J, Elbert A, Petren KM, et al. Combining international registries: a matching algorithm using longitudinal data. Pediatr Pulmonol. 2016; 51:S194–S485.
73. Blackman SM, Deering-Brose R, McWilliams R, et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology. 2006; 131:1030–1039.
74. Goss CH, Mayer-Hamblett N. The yin and yang of indoor airborne exposures to endotoxin. Am J Respir Crit Care Med. 2013; 188:1181–1181.
75. Leung DH, Ye W, Molleston JP, et al. Baseline ultrasound and clinical correlates in children with cystic fibrosis. J Pediatr. 2015; 167:862–868.e862.
76. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials. 2009; 30:256–268.
77. ClinicalTrials.gov. Standardized Treatment of Pulmonary Exacerbations II. 2016; https://clinicaltrials.gov/ct2/show/NCT02781610?term=stop+cystic+fibrosis&rank=2. Accessed March 23, 2017.
78. Cystic Fibrosis Foundation Clinical Care Guidelines. https://www.cff.org/Care/Clinical-Care-Guidelines/. Accessed March 24, 2017.
79. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. CHEST. 2004; 125:1S–39S.
80. Johnson C, Butler SM, Konstan MW, Morgan W, Wohl ME. Factors influencing outcomes in cystic fibrosis: a center-based analysis. CHEST. 2003; 123:20–27.
81. Padman R, Werk LN, Ramirez-Garnica G, Ye G, Nathanson I. Association between practice patterns and body mass index percentile in infants and young children with cystic fibrosis. J Cyst Fibros. 2008; 7:385–390.
82. Morgan WJ, Wagener JS, Yegin A, et al. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. J Pediatr. 2013; 163:1152–1157 e1152.
83. 1 decline in children with cystic fibrosis. Ann Am Thorac Soc. 2017; 14:937–942.
84. Quittner AL, Abbott J, Georgiopoulos AM, et al. International committee on mental health in cystic fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax. 2016; 71:26–34.
85. Schechter MS, Fink AK, Homa K, Goss CH. The Cystic Fibrosis Foundation Patient Registry as a tool for use in quality improvement. BMJ Qual Saf. 2014; 23:i9–14.
86. Berlinski A, Chambers MJ, Willis L, Homa K, Com G. Redesigning care to meet national recommendation of four or more yearly clinic visits in patients with cystic fibrosis. BMJ Qual Saf. 2014; 23:i42–i49.
87. 1 as part of a multifaceted program to improve CF outcomes. Pediatr Pulmonol. 2016; 51:S194–S485.
88. Realpe A, Wallace L. What is Co-Production? London: The Health Foundation; 2010.